95 related articles for article (PubMed ID: 18418213)
81. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
82. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
Choe MS; Chen Z; Klass CM; Zhang X; Shin DM
Clin Cancer Res; 2007 May; 13(10):3015-23. PubMed ID: 17505004
[TBL] [Abstract][Full Text] [Related]
83. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
84. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.
Matheny KE; Barbieri CE; Sniezek JC; Arteaga CL; Pietenpol JA
Laryngoscope; 2003 Jun; 113(6):936-9. PubMed ID: 12782800
[TBL] [Abstract][Full Text] [Related]
85. An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma.
Yoo GH; Subramanian G; Boinpally RR; Iskander A; Shehadeh N; Oliver J; Ezzat W; Piechocki MP; Ensley JF; Lin HS; Shibuya TY; Polin L; Parchment RE
Arch Otolaryngol Head Neck Surg; 2005 May; 131(5):418-29. PubMed ID: 15897421
[TBL] [Abstract][Full Text] [Related]
86. Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma.
Saigal B; Glisson BS; Johnson FM
Anticancer Drugs; 2008 Jun; 19(5):465-75. PubMed ID: 18418213
[TBL] [Abstract][Full Text] [Related]
87. [Focus on cellular pharmacology of docetaxel].
Armand JP
Bull Cancer; 2003 Dec; 90(12):1067-70. PubMed ID: 14715427
[TBL] [Abstract][Full Text] [Related]
88.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
89.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
90.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
91.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
92.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
93.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
94.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
95.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
